PDE5A and liver dysplastic nodule: Thus, there is an opportunity to combine CTSC and PDE5A screening with urine protein, urine protein/creatinine ratio, 24-hour urinary protein quantitation, and urinary protein excretion rate to predict the risk of DN in diabetic patients.